Albert Labs International Corp. · CSE:ABRT
Albert Labs International — Investor Presentation (February 2022)
37 slides from Albert Labs International's investor presentation, February 2022
Slide 1: Addressing Mental Health and Wellness
Addressing Mental Health and Wellness Presentation - February 2022 Accelerating access to psychedelics-based medicines for patients with urgent and unmet needs The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 200
Slide 2: Albert Labs Overview
Albert Labs Overview Albert Labs is a laboratory-based, natural drug development enterprise using an accelerated regulatory pathway to deliver faster access to novel mental health therapy for patients with urgent and unmet needs Developing Pharmaceuticals for the Large & Growing Mental Health Market
Slide 3: Strategy to Revenue & Profit
Strategy to “Accelerating access to psychedelic-based Revenue & Profit medicines for patients with urgent and unmet needs” Dr Michael Raymont Chief Executive Officer Psilocybin & psychedelics Fast & credible regulatory Focused initial indication, have already shown to be pathway - Real World Cancer Rel
Slide 4: Addressing Mental Health
Addressing 1 billion people 17% of the UK are suffering 17% of the entire UK adult Mental Health Suffer from anxiety and depression disorders population are now prescribed a psychiatric drug each year 17 worldwide2 Mental health conditions remain the single largest cause of disability in the KRN-101 f
Slide 5: Management Team
Team Highlights Dr Michael Raymont Prof. Jo Neill - Advisory Board Chair Chief Executive Officer BSc Pharmacology, PhD in Psychopharmacology ● Well seasoned leader with experience in venture capital & healthcare ● Jo is the Professor of Psychopharmacology at the University Manchester. investment. Rese
Slide 6: Global Supply Chain & Operations
Global Supply Chain & Operations Manchester, UK ● UK Specials & Clinical Trial Manufacture ○ API Production Burnaby, Canada ○ Finished Product Lines ● Home Office License ● Production Scale-up R&D ● MHRA Compliant EU GMP ○ Formulation R&D ○ Bio-reactor Coimbra, Portugal ● API Production ● Health Canad
Slide 7: The Psilocybin Solution
Breakthrough Therapy The Psilocybin The FDA has granted two breakthrough therapy Solution designations for psilocybin7 The MHRA has granted two Psychedelic medicines will change Innovation Passports for the way mental health is treated psychedelic therapy Already shown that psychedelic medicines are
Slide 8: Why Now & Why the UK?
Why Now & Why the UK? Changing opinions from policy makers & public attitudes now support UK Public Attitudes to psychedelic research Psilocybin Therapy YouGov poll - When informed about findings from clinical research Real World Evidence studies are an support for changing the law. increasingly acce
Slide 9: Industry Leading Partnerships
Industry Leading Partnerships → Access to expert physicians → Accessible patient pool → Cost-efficient data generation → Patient-motivated clinical team → Existing clinical resources → Local reimbursement
Slide 10: Quicker & Cost-effective Commercialisation
Quicker & Cost-effective Commercialisation Randomised Controlled Trials 5-12 Years Preclinical RCT’s Registered Medicine Safety & MHRA Trial Data Submission (MHRA Authorised Phase 1 Phase 2 Phase 3 Stability Approval & EMA) Medicine Healthy Volunteers Treating Patient Needs Commercial Real World Evid
Slide 11: Fast Access to UK & European Markets
Fast Access to UK & European Markets ILAP - A new UK RWE Accelerated Global market licensing pathway Vaccines to Market access schemes To accelerate access and reduce Early recognition from the UK Schemes such as Project the time to market for patients with Regulators (MHRA) enabled fast Orbis16 all
Slide 12: Drug Development Pipeline
Drug Development Pipeline Expert Team Continued Expansion with Other Denzil Phillips Naturally Occurring Compounds Medicinal Plant Licencing & Compliance. With a focus on natural risk mitigated compounds Practical Guide to Licensing Herbal Medicinal Products with a history of safe & tolerable use Pr
Slide 13: From Bench to Bedside
From Bench to Bedside Natural Psilocybin Mycelium Enabling scale; Proven safe; Preferred by patients. We can study improving medical properties by Lead Trial Center exploring a range of natural active compounds. The Christie is the largest single site cancer centre in Europe, servicing a population
Slide 14: API Bioreactor, IP Protected
API Bioreactor, Increased: IP Protected ● ● Cultivation speed Production capability ● Control over variables Provisional Patent Submitted to ● Consistency for medicines United States Patent Office ● Synergistic bioactives Confidential Consistent, scalable and cost effective production Decreased: ● Risk
Slide 15: Real World Evidence: A Risk-Mitigated Approach
Real World Evidence: A Risk-Mitigated Approach Focus on natural compounds with previous human evidence to address unmet needs with a Real World accelerated approach ● Focus on commercialising compounds with existing safety and efficacy data ● Use Real World Evidence to achieve faster Maximising chance
Slide 16: Scalable Strategy for Revenue
Scalable Strategy for Revenue Patient revenue: £5,000-£7,500 The UK cancer Cost of goods: £3,000 Margin: 50-60% related distress £0 £3,000 £7,500 market is £5B Revenues begin: Q4 2022 Break-even point: 1,180 patients (Projected for KRN-101 in the UK market) Patients 250 Patient Cohort Expand Patient
Slide 17: Timeline to Commercialisation
Timeline to commercialisation Patient Study Commences KRN-101 administered to initial patient Develop and trial KRN-101 to address pools at the largest cancer centre in Europe cancer-related anxiety and depression Study Development MHRA Sign Off & ILAP Application Interim Publications Design RWE prot
Slide 18: Psychedelic Comparables
Psychedelic Comparables Estimated Valuation Companies Molecule Indication Stage Approval (CAD)* Neuropsychiatric Arketamine, ATAI Germany Diseases, Phase 2 Undisclosed 1B Ibogaine, & more Opioid Addiction Treatment Compass Pathways US Psilocybin Resistant Phase 2b 2025 790M Depression Opioid Addicti
Slide 19: Projections & Use of Proceeds
Projections & Use of Proceeds *All in C$ Projections Operations Operations Operations Use of Proceeds Amounts 2022 2023 2024 Proportion of UK Market - Cancer related anxiety 0.025% 0.3% 1% RWE Study 900,000 Recruited Patients 250 3,000 10,000 Canadian Lab 500,000 Operations Expected Revenue 2,550,00
Slide 20: Investment Terms
$0.25 Q1 | 2022 Concurrent raise of 16 Subject to exchange approval, million shares with a Albert Labs to list on the $4m dollar target Canadian Securities Exchange Investment Valuation ● C$12m Pre-Money Valuation based on 48m shares Terms ● C$16m Post-Money Valuation based on the additional C$4m ra
Slide 21: To Summarise - Speed to Market, Revenue & Profit
To Summarise - Speed to Market, Revenue & Profit Delivering Safe & Effective Fast & Early Approval With A Differentiated Strategy Natural Medicines To The Expansion Into New And Using Rwe To Accelerate Mental Health Market Larger Markets Medical Authorisation Experienced Team That Can A Risk Mitigated,
Slide 22: Contact us
Contact us For further information please contact: Tel: +44 7828 008237 Email: info@albertlabs.com
Slide 23: Further Reading
Further Reading ● Directors ● Senior Team ● Clinical Advisors ● Scientific Advisors ● References ● Disclaimer ● Forward Looking Information ● Statutory Rights Of Action
Slide 24: Directors
Directors Dr. Michael Raymont Katie Shelton-Innes Chand Jagpal CEO Director Director Dr Raymont's career has consisted of Katie Shelton-Innes, an experienced 20+ years of experience in the medical leadership roles. He ran the National investment banking professional with a focus cannabis, agricultur
Slide 25: Senior Team
Senior Team Dr. Malcolm Graeme McFarlane Barratt-Johnson Ali Gulamhusein Chief Commercial Officer Chief Development Officer Chief Medical Officer 30+ years in the pharmaceutical industry, Dr Barratt-Johnson previously held positions 15+ years of engineering experience, having held senior management at the
Slide 26: Clinical Advisory Board
Clinical Advisory Board Prof. Jo Neill Dr. Sara Tai Prof. Sam Ahmedzai BSc Pharmacology, PhD in BA(Hons), MSc, D.ClinPsy, FRCPGlas, FRCP, FRCPE Psychopharmacology Cpsychol/Impact Dr Neill is the Professor of Dr Tai is a Senior Lecturer in Clinical Professor Sam Ahmedzai is the NIHR Psychopharmacolog
Slide 27: Scientific Advisory Board
Scientific Advisory Board Parminder Singh Dr. Naeem Khan Dr Jonathan Curry IP protection, Licensing & EU-GMP Expertise Microbiological Expertise Patents Parminder Singh has 25 years of technical, Naeem holds a PhD in Chemistry and has over Dr Curry holds a PhD in Environmental operations, internation
Slide 28: References
1. References Lemke, Thomas L.; Williams, David A. (2008). Foye's Principles of Medicinal Chemistry (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 568–600. 2. Mental health matters - The Lancet Global Health. (n.d.). Retrieved October 31, 2021, from https://www.thelancet.com/journals/la
Slide 29: Appendix 1
Appendix 1 Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby and Brian L Schmidt. - November 30, 2016 Rapid and sustained symptom reduction following psilocybin tre
Slide 30: Appendix 2
Appendix 2 Roland R Griffiths, Matthew W Johnson1, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano and Margaret A Klinedinst - November 30, 2016 Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening
Slide 31: Appendix 3
Appendix 3 Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer - September 6, 2010 Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer [Excerpts from the publication] Methods: Twelve adults with
Slide 32: Disclaimer
DISCLAIMER >> NOT FOR DISSEMINATION TO THE GENERAL PUBLIC This document is a presentation (the “Presentation”) concerning certain general background information about the activities undertaken by Albert Labs Inc. (the “Company”) current as of March 29, 2021, unless stated otherwise. It is informatio
Slide 33: Forward-Looking Information (1)
Forward-Looking Information (1) >> This Presentation contains “forward-looking information” within the meaning of applicable Canadian securities laws and (“forward-looking statements”). Forward-looking statements in this Presentation include, but are not limited to, statements with respect to: the C
Slide 34: Forward-Looking Information (2)
Forward-Looking Information (2) >> Statutory Rights Of Action This Presentation may be considered an offering memorandum thereby granting the potential purchasers statutory rights and contractual rights of action. Securities legislation in certain provinces of Canada may provide a purchaser with rem
Slide 35: Statutory Rights Of Action (1)
Statutory Rights Of Action (1) >> Securities legislation in certain provinces in Canada provides certain purchasers of securities pursuant to an offering memorandum with a right of action for damages or rescission, in addition to any other rights they may have at law, where the offering memorandum c
Slide 36: Statutory Rights Of Action (2)
Statutory Rights Of Action (2) >> No action to enforce a right of rescission may be commenced more than 180 days after the date of the transaction that gave rise to the cause of action and a purchaser must commence an action for damages within the earlier of: (i) one year after such purchaser first h
Slide 37: Statutory Rights Of Action (3)
Statutory Rights Of Action (3) >> In no case will the amount recoverable in any action exceed the price at which the securities were offered to the purchaser and if the purchaser is shown to have purchased the securities with knowledge of the misrepresentation, no person will be liable. No action to
Albert Labs International — Investor Presentation (February 2022) on 6ix